Meddenovo Drug Design
Private Company
Funding information not available
Overview
Meddenovo Drug Design is a private, pre-clinical stage biotech founded in 2019, specializing in AI-driven cyclic peptide discovery. Its proprietary platform, Mexa, enables the exploration of tens of millions of cyclic peptide candidates per target, integrating generative AI with biophysical validation to deliver high-quality hits rapidly. The company has secured a pre-seed funding round, won the i-Lab 2025 award, and entered a significant co-development partnership with Daiichi-Sankyo, positioning it as an emerging player in the next-generation therapeutics space. Meddenovo employs a platform-plus-partnership business model and is currently pre-revenue.
Technology Platform
Mexa, an AI-powered platform for de novo design of cyclic peptides. It combines large-scale generative AI with physics-based modeling and evaluation to explore tens of millions of candidates per target and deliver high-confidence hits without the need for prior experimental data.
Opportunities
Risk Factors
Competitive Landscape
Meddenovo operates in the competitive AI-driven drug discovery sector, competing with public companies like Exscientia and Recursion, as well as numerous private peers. Its niche focus on cyclic peptides differentiates it, but it still competes with other computational peptide design firms and traditional discovery methods. The partnership with Daiichi-Sankyo provides a key competitive advantage and validation.